Agenta Biotechnologies Inc is discovery-based biotechnology corporation developing implantable devices (e.g. membranes, sponges, or micro-particles) to stimulate and improve the healing and repair process. The technology enables localized proteoglycan expression with or without growth factors to in order to promote healing, provide structure and to increase both blood supply as well as tissue hydration. These therapeutics can be applied to bone, cartilage, ligaments, discs in the spine, and skin, or serve as coatings for vascular stents and implants. This technology will lead to improvements in spine and vertebral disc treatments, better skin healing after burn wounds, healing of sores that wonât respond to current therapies in diabetic patients or in the elderly and repair of damaged skin from sun or age. The firmâs work has produced technologies that create both near-term commercial operations and high-value long-term development opportunities. These technologies include a patented synthetic bone graft with published superiority to leading competitors; a strong, pliable, yet dissolvable, surgical barrier membrane made from a specialized sugar in a patented manner for application to bone, cartilage, ligament, skin and wound healing, breast reconstruction and hernia repair. The membrane also serves as a delivery device to allow slow-release drugs to be resorbed; and a new, patented skin substitute for the healing of large skin ulcers or chronic ulcers of the foot and leg associated with diabetes and a
